Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)
Cefalexin
Virbac
QJ01DB01
Cefalexin
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Cats, Dogs
Antimicrobial
Authorized
2005-10-24
Revised: December 2022 AN: 02162/2022 Page 1 of 6 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rilexine 75 mg Tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: -Active substance Cefalexin …………………………………………….75 mg (as Cefalexin Monohydrate) For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Creamy oblong tablets with small brown spots with a score-line. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of bacterial skin infections in dogs (including deep and superficial pyodermas) caused by organisms susceptible to Cefalexin. For the treatment of cutaneous and subcutaneous infections (wounds and abscesses) in cats caused by organisms susceptible to Cefalexin. For the treatment of urinary-tract infections in cats and dogs (including nephritis and cystitis) caused by organisms susceptible to Cefalexin. 4.3 CONTRA-INDICATIONS Do not use in animals which are known to be hypersensitive to penicillins and cephalosporins. Do not use in rabbits, guinea pigs, hamsters and gerbils. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Revised: December 2022 AN: 02162/2022 Page 2 of 6 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight or kittens under 9 weeks of age. Use of the product deviating from the instructions given in the S.P.C. may increase the prevalence of bacteria resistant to Cefalexin and may decrease the effectiveness of treatment with other cephalosporins and peni Izlasiet visu dokumentu